Abstract
Muramyl dipeptide (MDP) is a synthetic glycopeptide analog of a part of bacterial peptidoglycan (13). It represents the minimal adjuvant-active structure and has also been shown to stimulate nonspecific resistance in animals subsequently infected (9). These effects have been demonstrated after injecting MDP in saline by different routes. The synthesis of MDP was followed by the preparation of a large number of derivatives with the hope of determining structure-activity relationships (12, 15), or at least of selecting immunostimulating compounds, which did not retain several side effects inherent to MDP administration (6, 24). Such an evaluation has allowed us to select an MDP derivative called Murabutide which is undergoing clinical trials with conventional vaccines after its safety has been established by animal toxicological studies, and in a phase I clinical trial.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bauss, F., Dröge, W. and M’dnnel, D. N., 1985, Tumor necrosis factor mediates endotoxic effects in mice. Infect. Immun. 55: 1622.
Beutler, B., Milsark, I. W. and Cerami, A. C., 1985, Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229: 869.
Bloksma, N., Hofhuis, F. M. and Willers, J. M., 1984, Endotoxin-induced antitumor activity in the mouse is highly potentiated by muramyl dipeptide. Cancer Letters 23: 159.
Bloksma, N., Hof huis, F. M. and Willers, J. M., 1984, Muramyl dipeptide is a powerful potentiator of the antitumor action of various tumor necrotizing agents. Cancer Immunol. Immunother. 17: 154.
Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N. and Williamson, B., 1975, An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA 72: 3666.
Chedid, L., 1983, Muramyl peptides as possible endogenous immunopharmacological mediators. Microbiol. Immun. 27: 723.
Chedid, L., Audibert, F., Bona, C., Damais, C., Parant, F. and Parant, M., 1975, Biological activities of endotoxin detoxified by alkylation. Infect. Immun. 12: 714.
Chedid, L., Parant, M., Audibert, F., Riveau, G., Parant, F., Lederer, E., Choay, J. and Lefrancier, P., 1982, Biological activity of a new synthetic muramyl peptide adjuvant devoid of pyrogenicity. Infect. Immun. 35: 417.
Chedid, L., Parant, M., Parant, F., Lefrancier, P., Choay, J. and Lederer, E.,, 1977, Enhancement of non-specific immunity to Klebsiella pneumoniae infection by a synthetic immunoadjuvant (N-acetyl-muramyl-Lalanyl-D-isoglutamine) and several analogs. Proc. Natl. Acad. Sci. USA 74: 2089.
Chedid, L., Parant, M., Parant, F., Audibert, F., Lefrancier, P., Choay, J. and Sela, M., 1979, Enhancement of certain biological activities of muramyl dipeptide derivatives after conjugation to a multi-poly(DLalanyl)-poly(L-lysine) carrier. Proc. Natl. Acad. Sci. USA 76: 6557.
Havell, E. A., 1987, Production of tumor necrosis factor during murine Listeriosis. J. Immunol. 139: 4225.
Kotani, S., Takeda, H., Tsujimoto, M., Ogawa, T., Mori, Y., Koga, T., Iribe, H., Tanaka, A., Nagao, S., McGhee, J. R., Michalek, S. M., Kawata, S., Shiba, T. and Kusumoto, S., 1983, Lipophilic muramyl peptides and synthetic lipid A analogs as immunomodulators, in: “Progress in Immunology V,” Y. Yamamura and T. Tada, eds., Academic Press, Japan.
Lederer, E., 1980, Syntheric immunostimulants derived from the bacterial cell wall. J. Med. Chem. 23: 819.
Lefrancier, P., Derrien, M., Jamet, X., Choay, J.-, Lederer, E., Audibert, F., Parant, F., Parant, M. and Chedid, L., 1982, Apyrogenic adjuvant-active N-acetylmuramyl dipeptides. J. Med. Chem. 25: 87.
Lefrancier, P. and Lederer, E., 1981, Chemistry of synthetic immunomodulant muramyl peptides. Prog. Chem. Org. Nat. Prod. 40: 1.
Lehmann, V., Freudenberg, M. A. and Galanos, C., 1987, Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and Dgalactosamine-treated mice. J. Exp. Med. 165: 657.
Level, M., Bernard, J. M., Lefrancier, P. and Phillips, N., 1984, New lipophilic muramyl dipeptide derivatives: synthesis and biological activity of their liposome encapsulated formulation, in: “Forum Peptides,” B. Castro and J. Martinez, eds., Centre de Pharmacologie, Montpellier, France, p. 250.
Mönnel, D., Meltzer, M. S. and Mergenhagen, S. E., 1980, Generation and characterization of a lipopolysaccharide-induced and serum-derived factor for tumor cells. Infect. Immun. 28: 204.
Niitsu, Y., Watanabe, N., Sone, H., Neda, H. and Urushizaki, I., 1985, T cell involvement in production of tumor necrosis factor: reconstitution experiment with nude mice. Japanese J. Cancer Res. 76: 395.
Old. L. J., 1976, Tumor necrosis factor. Clin. Bull. 6: 118.
Palladino, M. A., Shalaby, M. R., Kramer, S. M., Ferraiolo, B. L., Baughman, R. A., Deleo, A. B., Crase, D., Marafino, B., Aggarwal, B. B., Figari, I. S., Liggitt, D. and Patton, J. S., 1987, Characterization of the antitumor activities of human tumor necrosis factor-a and the comparison with other cytokines: induction of tumor specific immunity. J. Immunol. 138: 4023.
Parant, M., 1983, Effect of LPS on nonspecific resistance to bacterial infections, in: “Beneficial Effects of Endotoxins,” A. Nowotny, ed.. Plenum Press, New York, p. 179.
Parant, M., 1988, Role of tumor necrosis factor in nonspecific stimulation of the mouse resistance to infections, in: “Tumor Necrosis Factor/Cachectin, Lymphotoxins and Related Cytokines,” H. Kirchner and B. Bonavida, eds., Karger, Basel, p. 234.
Parant. M. and Chedid, L., 1984, Stimulation of nonspecific resistance to infections by synthetic immunoregulatory agents. Infection 12: 230.
Parant, M. and Chedid, L., 1987, Muramyl dipeptides, host immunity and enhancement, in: “Antibiosis and Host Immunity,” A. Szentivanyi, H. Friedman and G. Gillissen, eds., Plenum Press, New York, p. 291.
Parant, M., Parant, F. and Chedid, L., 1978, Enhancement of the neonate’s non specific immunity to Klebsiella infection by muramyl dipeptide, a synthetic immunoadjuvant. Proc. Natl. Acad. Sci. USA 75: 3395.
Parant, M., Parant, F., Vinit, M. A. and Chedid. L., 1987, Action protectrice du tumor necrosis factor (TNF) obtenu par recombinaison gönötique contre l’infection expörimentale bactörienne et fongique. C. R. Acad. Sci. Paris 304: 1.
Ribi, E. E., Cantrell, J. L., VonEschen, K. B. and Schwartzman, S. M., 1979, Enhancement of endotoxic shock by N-acetyl-L-alanyl-(L- seryl)-Disoglutamine (muramyl dipeptide), Cancer Res. 39: 4756.
Ribi, E., Parker, R., Strain, S. M., Mizuno, Y., Nowotny, A., VonEschen, K. B., Cantrell, J. L., McLaughlin, C. A., Hwang, K. M. and Goren, M. B., 1979, Peptides as requirement for immunotherapy of the guinea-pig line-10 tumor with endotoxins. Cancer Immunol. Immunother. 7: 43.
Rothstein, J. L. and Schreiber, H., 1988, Synergy between tumor necrosis factor and bacterial products causes hemorrhagic necrosis and lethal shock in normal mice. Proc. Natl. Acad. Sci. USA 85: 607.
Ruff, M. R. and Gifford, G. E., 1981, Tumor necrosis factor, in: “Lymphokines Vol. 2,” E. Pick, ed., Academic Press, New York, p. 235.
Tracey. K. J., Beutler, B., Lowry, S. F., Merryweather, J., Wolpe, S., Milsark, I. W., Hariri, R. J., Fahey, T. J., Zentella, A., Albert, J. D.. Shires, G. T, and Cerami, A.. 1986. Shock and tissue injury induced by recombinant human cachectin. Science 234: 470.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer Science+Business Media New York
About this chapter
Cite this chapter
Parant, M., Chedid, L. (1990). Various Aspects of Synergism between Endotoxin and MDPs. In: Friedman, H., Klein, T.W., Nakano, M., Nowotny, A. (eds) Endotoxin. Advances in Experimental Medicine and Biology, vol 256. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-5140-6_47
Download citation
DOI: https://doi.org/10.1007/978-1-4757-5140-6_47
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-5142-0
Online ISBN: 978-1-4757-5140-6
eBook Packages: Springer Book Archive